Adhering to the advice of a May panel of rheumatologists and drug safety experts, the FDA has refused to approve NicOx SA's experimental osteoarthritis drug naproxcinod until more studies are completed, which sent the French drugmaker's stock into a tailspin Thursday. (BioWorld Today) Read More
